Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H2 2018’, provides an overview of the Secondary (Hypogonadotropic) Hypogonadism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Secondary (Hypogonadotropic) Hypogonadism and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Secondary (Hypogonadotropic) Hypogonadism

- The report reviews pipeline therapeutics for Secondary (Hypogonadotropic) Hypogonadism by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Secondary (Hypogonadotropic) Hypogonadism therapeutics and enlists all their major and minor projects

- The report assesses Secondary (Hypogonadotropic) Hypogonadism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Secondary (Hypogonadotropic) Hypogonadism

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Secondary (Hypogonadotropic) Hypogonadism pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Diurnal Group Plc

Merck & Co Inc

Mereo Biopharma Group Plc

Repros Therapeutics Inc

Diurnal Group Plc

Merck & Co Inc

Mereo Biopharma Group Plc

Repros Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Secondary (Hypogonadotropic) Hypogonadism - Overview

Secondary (Hypogonadotropic) Hypogonadism - Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Secondary (Hypogonadotropic) Hypogonadism - Overview

Secondary (Hypogonadotropic) Hypogonadism - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Secondary (Hypogonadotropic) Hypogonadism - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Secondary (Hypogonadotropic) Hypogonadism - Companies Involved in Therapeutics Development

Diurnal Group Plc

Merck & Co Inc

Mereo Biopharma Group Plc

Repros Therapeutics Inc

Secondary (Hypogonadotropic) Hypogonadism - Drug Profiles

corifollitropin alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

enclomiphene citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IAS-167A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Kisspeptin-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leflutrozole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leuprolide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VERU-722 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Secondary (Hypogonadotropic) Hypogonadism - Dormant Projects

Secondary (Hypogonadotropic) Hypogonadism - Discontinued Products

Secondary (Hypogonadotropic) Hypogonadism - Product Development Milestones

Featured News & Press Releases

Jan 26, 2018: Repros Announces Negative Opinion From the EMA for Enclomiphene

Dec 15, 2017: Repros Therapeutics Receives Feedback Following an Oral Explanation with the European Medicines Agency

Sep 05, 2017: Completion of Patient Enrolment in Phase 2b dose-confirmation study of BGS-649 for the treatment of hypogonadotropic hypogonadism

Mar 07, 2017: Mereo BioPharma Group: Positive recommendation for BGS-649 Phase 2b trial following planned IDMC interim analysis

Dec 06, 2016: FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism

Oct 05, 2016: Repros Announces Acceptance of Dossier for Enclomiphene for Secondary Hypogonadism by European Authorities

Sep 12, 2016: Repros Announces Submission of MAA to the European Medicines Agency for Enclomiphene in the Treatment of Secondary Hypogonadism

Aug 15, 2016: Repros Provides Six Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men

Jun 01, 2016: Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism and 3 Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men

Mar 15, 2016: Repros Announces Initiation of Formal Approval Process by the European Medicines Agency

Feb 16, 2016: Repros Completes Randomization of Enclomiphene Phase 2 Proof of Concept Study in Obese Secondary Hypogonadal Men

Feb 08, 2016: Repros Holds Meeting With FDA to Discuss Complete Response Letter for Enclomiphene in the Treatment of Secondary Hypogonadism

Jan 11, 2016: Repros Announces Court of Appeals' Affirmation of Summary Judgment in Favor of the Company

Jan 04, 2016: Repros Updates Enclomiphene Program

Dec 01, 2015: Repros Therapeutics Receives Complete Response Letter From FDA for Enclomiphene

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, H2 2018

Number of Products under Development by Companies, H2 2018

Number of ...

List of Tables

Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Diurnal Group Plc, H2 2018

Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Merck & Co Inc, H2 2018

Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H2 2018

Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Repros Therapeutics Inc, H2 2018

Secondary (Hypogonadotropic) Hypogonadism - Dormant Projects, H2 2018

Secondary (Hypogonadotropic) Hypogonadism - Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, H2 2018

Number of Products under Development by Companies, H2 2018

Number of ...

List of Figures

Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports